Antiprotozoal activities of phospholipid analogues

Molecular and Biochemical Parasitology

Volumn 126, Issue 2, 2003, Pages 165-172

  Croft, Simon L ^a   Seifert, Karin ^a   Duchêne, Michael ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Miltefosine; Phospholipid analogues; Protozoa

Indexed keywords

MILTEFOSINE; PHOSPHOLIPID DERIVATIVE; PHOSPHORYLCHOLINE;

ACANTHAMOEBA; ANTIPROTOZOAL ACTIVITY; CANCER CELL; CELL MEMBRANE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; ENTAMOEBA HISTOLYTICA; GASTROINTESTINAL SYMPTOM; HUMAN; LEISHMANIA; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROTOZOON; REVIEW; SIDE EFFECT; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; TUMOR CELL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; LEISHMANIA; PARASITIC SENSITIVITY TESTS; PHOSPHOLIPID ETHERS; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOSOMA;

ACANTHAMOEBA; ENTAMOEBA HISTOLYTICA; PROTOZOA; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI;

EID: 0037325060     PISSN: 01666851     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-6851(02)00283-9     Document Type: Review

References (62)

1. Munder P.G., Modolell M., Ferber E., Fischer H. Phospholipide in quarzgeschaedigten Makrophagen. Biochem. Z. 344:1966;310-313.
2. Andreesen R., Modolell M., Weltzien H.U.et al. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res. 38:1978;3894-3899.
3. Munder PG, Modolell M, Bausert W, Oettgen HF, Westphal O. Alkyl-lysophospholipids in cancer therapy. In: Hersh EM, editor. Augmenting agents in cancer therapy. New York: Raven Press; 1981, p. 441-58.
4. Brachwitz H., Arndt D., Fichtner I., Langen P. Cytostatic activity of synthetic O-alkylglycerolipids. Lipids. 22:1987;897-903.
5. Ferber E, Koerner E, Schmidt B, Peskar BA, Anders C. Part IV: phospholipid changes accompanying physiological events. In: Kates M, Kuksis A, editors. Membrane fluidity: biophysical techniques and cellular regulation. Clifton, NJ: The Human Press, Inc.; 1980, p. 239-63.
6. Eibl H. Phospholipid synthesis. Oxazaphospholanes and dioxaphospholanes as intermediates. Proc. Natl. Acad. Sci. USA. 75:1978;4074-4077.
7. Eibl H., Unger C. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev. 17:1990;233-242.
8. Benveniste J., Tence M., Varenne P., Bidault J., Boullet C., Polonsky J. Semi-synthesis and proposed structure of platelet-activating factor (PAF): PAF-acether an alkyl ether analog of lysophosphatidylcholine. C R Seances Acad. Sci. D. 289:1979;1037-1040.
9. Demopoulos C.A., Pinckard R.N., Hanahan D.J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J. Biol. Chem. 254:1979;9355-9358.
10. Tsushima S., Yoshioka Y., Tanida S., Nomura H., Nojima S., Hozumi M. Syntheses and antimicrobial activities of alkyl lysophospholipids. Chem. Pharm. Bull. (Tokyo). 30:1982;3260-3270.
11. Achterberg V., Gercken G. Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 23:1987;117-122.
12. Achterberg V., Gercken G. Metabolism of ether lysophospholipids in Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 26:1987;277-287.
13. Croft S.L., Neal R.A., Pendergast W., Chan J.H. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 36:1987;2633-2636.
14. Herrmann H.O., Gercken G. Metabolism of 1-O-[1′-14C]octadecyl-sn-glycerol in Leishmania donovani promastigotes. Ether-lipid synthesis and degradation of the ether bond. Mol. Biochem. Parasitol. 5:1982;65-76.
15. Berdel W.E. Membrane-interactive lipids as experimental anticancer drugs. Br. J. Cancer. 64:1991;208-211.
16. Croft S.L., Neal R.A., Thornton E.A., Herrmann D.B. Antileishmanial activity of the ether-phospholipid ilmofosine. Trans. R Soc. Trop. Med. Hyg. 87:1993;217-219.
17. Croft S.L., Snowdon D., Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38:1996;1041-1047.
18. 3 (edelfosine) and amphotericin B. Acta Trop. 81:2002;151-157.
19. Lux H., Hart D.T., Parker P.J., Klenner T. Ether-lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkylphospholipid analogues. Adv. Exp. Med. Biol. 416:1996;201-211.
20. Bourass J., Loiseau P.M., Bories C., Letourneux Y. Antileishmanial activity of rac-1-dodecyl-2-octanamido-2-deoxy-glycerophosphocholine, a new dialkylglycerophosphocholine, in vitro. Ann. Trop. Med. Parasitol. 90:1996;559-561.
21. Rodrigues C.O., Dutra P.M.L., Souto-Padron T., Cordeiro R.S.B., Lopes A.H.C.S. Effect of platelet-activating factor on cell differentiation of Trypanosoma cruzi. Biochem. Biophys. Res. Commun. 223:1996;735-740.
22. Lopes A.H.C.S., Dutra P.M.L., Rodrigues C.O., Soares M.J., Angluster J., Cordeiro R.S.B. Effect of platelet-activating factor on the process of cellular differentiation of Herpetomonas muscarum muscarum. J. Euk. Microbiol. 44:1997;321-325.
23. Unger C., Maniera T., Kaufmann-Kolle P., Eibl H. In vivo antileishmanial activity of hexadecylphosphocholine and other alkylphosphocholines. Drugs of Today. 34(suppl. F):1998;133-140.
24. Brachwitz H., Vollgraf C. Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmac. Ther. 66:1995;39-82.
25. Rybczynska M., Spitaler M., Knebel N.G., Boeck G., Grunicke H., Hofmann J. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol. 62:2001;765-772.
26. Croft S.L. Monitoring drug resistance in leishmaniasis. Trop. Med. Int. Health. 6:2001;899-905.
27. Santa-Rita R.M., Santos Barbosa H.S., Meirelles M.N.S.L., de Castro S.L. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. 75:2000;219-228.
28. Lira R., Contreras L.M., Santa-Rita R.M., Urbina J.A. Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother. 47:2001;537-546.
29. Konstantinov S.M., Kaminsky R., Brun R., Berger M.R., Zillmann U. Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies. Acta Trop. 64:1997;145-154.
30. Marschner M., Kötting J., Eibl H., Unger C. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother. Pharmacol. 31:1992;18-22.
31. Kuhlencord A., Maniera T., Eibl H., Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 36:1992;1630-1634.
32. Le Fichoux Y., Rousseau D., Ferrua B.et al. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob. Agents Chemother. 42:1998;654-658.
33. Murray H.W. Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob. Agents Chemother. 44:2000;3235-3236.
34. Murray H.W., Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. 181:2000;795-799.
35. Escobar P., Yardley V., Croft S.L. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. 45:2001;1872-1875.
36. ®) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans. R Soc. Trop. Med. Hyg. 93:1999;85-90.
37. Sundar S., Rosenkaimer F., Makharia M.K.et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 352:1998;1821-1823.
38. Sundar S., Gupta L.B., Makharia M.K., Singh M.K.et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann. Trop. Med. Parasitol. 93:1999;589-597.
39. Jha T.K., Sundar S., Thakur C.P.et al. Miltefosine, an oral agent, for the treatment of Indian visceral Leishmaniasis. New Engl. J. Med. 341:1999;1795-1800.
40. Sundar S., Makharia A., More D.K.et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis. 31:2000;1110-1113.
41. Soto J., Toledo J., Gutierrez P.et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33:2001;57-61.
42. Arthur G., Bittman R. The inhibition of cell signaling pathways by antitumor ether-lipids. Biochim. Biophys. Acta. 1390:1998;85-102.
43. Wieder T., Reutter W., Orfanos C.E., Geilen C.C. Mechanism of action of phospholipid analogs as anticancer compounds. Prog. Lipid Res. 38:1999;249-259.
44. Überall F., Oberhuber H., Maly K., Zaknun J., Demuth L., Grunicke H.H. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 51:1991;807-812.
45. Heesbeen E.C., Verdonck L.F., Staal G.E., Rijksen G. Protein kinase C is not involved in the cytotoxic action of 1-octadecyl-2-O-methyl-sn-glycerol-3-phosphocholine in HL-60 and K562 cells. Biochem. Pharmacol. 47:1994;1481-1488.
46. Haase R., Wieder T., Geilen C.C., Reutter W. The phospholipid analogue hexadecylphosphocholine inhibits phosphoatidylcholine biosynthesis in Madin-Darby canine kidney cells. FEBS Lett. 288:1991;129-132.
47. Wieder T., Orfanos C.E., Geilen C.C. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog hexadecylphosphocholine. J. Biol. Chem. 273:1998;11025-11031.
48. Konstantinov S.M., Eibl H., Berger M.R. Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells. Cancer Chemother. Pharmacol. 41:1998;210-216.
49. 3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res. 57:1997;1320-1328.
50. Lux H., Heise N., Klenner T., Hart D., Opperdoes F.R. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. 111:2000;1-14.
51. Malaquias A.T., Oliveira M.M. Phospholipid signalling pathways in Trypanosoma cruzi growth control. Acta Trop. 73:1999;93-108.
52. Parsons M., Ruben L. Pathways involved in environmental sensing in trypanosomatids. Parasitol. Today. 16:2000;56-62.
53. Piacenza L., Peluffo G., Radi R. L-Arginine-dependent suppression of apoptosis in Trypanosoma cruzi: contribution of the nitric oxide and polyamine pathways. Proc. Natl. Acad. Sci. USA. 98:2001;7301-7306.
54. Fleer E.A., Berkovic D., Eibl H., Unger C. Investigations on the cellular uptake of hexadecylphosphocholine. Lipids. 28:1993;731-736.
55. Engelmann J., Henke J., Willker W.et al. Early stage monitoring of miltefosine induced apoptosis in KB cells by multinuclear NMR spectroscopy. Anticancer Res. 16:1996;1429-1440.
56. Berkovic D, Fleer EAM, Eibl H, Unger C. Effects of hexadecylphosphocholine on cellular function. In: Eibl H, Hilgard P, Unger C, editors. New drugs in cancer therapy. Prog Exp Tumor Res Basel: Karger, 1992;34:59-68.
57. Perez-Victoria J.M., Perez-Victoria F.J., Parodi-Talice A.et al. Alkyl-lysophospholipid resistance in multidrug resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. 45:2001;2468-2474.
58. Seifert K., Duchêne M., Wernsdorfer W.H.et al. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob. Agents Chemother. 45:2001;1505-1510.
59. Kötting J., Berger M.R., Unger C., Eibl H. Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations. Cancer Chemother. Pharmacol. 30:1992;105-112.
60. Jones D.B. Acanthamoeba - the ultimate opportunist? Am. J. Ophthalmol. 102:1986;527.
61. Walochnik J., Duchêne M., Seifert K.et al. Cytotoxic activity of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob. Agents Chemother. 46:2002;695-701.
62. Herwaldt B.L. Miltefosine - the long-awaited therapy for visceral leishmaniasis? N Engl. J. Med. 341:1999;1840-1842.